SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation is a research paper published in Science Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 203 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5K22HL125593
National Institutes of Health
Grant: R01HL119215
National Institutes of Health
Grant: R35GM138283
National Heart, Lung, and Blood Institute
Grant: 006223
National Institute of Allergy and Infectious Diseases
Grant: ZIA/AI001175
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: ZIA/DK075149
Malacological Society of London
Grant: T32DE007057
Kaz Deutsche Forschungsgemeinschaft
Grant: FR 3851/2-1
NHLBI
Grant: ZIA/Hl006223
NHLBI NIH HHS
Grant: K22 HL125593
NIDDK NIH HHS
Grant: R01 DK122624
Intramural NIH HHS
Grant: ZIA AI001175
Intramural NIH HHS
Grant: ZIA DK075149
Intramural NIH HHS
Grant: ZIA HL006223
National Institutes of Health
Grant: 5T32DE007057-42
Tissue Engineering and Regeneration
National Institutes of Health
Grant: 1ZIADK075149-06
Unravelling immunoregulatory circuits of tissue inflammation
National Institutes of Health
Grant: 1R01HL119215-01
A Hox-Wnt-Sox signaling axis regulates lung development, patterning and branching
National Institutes of Health
Grant: 1ZIADK013039-04
Molecular modeling of soluble proteins
National Institutes of Health
Grant: 1ZIAAI001175-13
Immunopathogenesis of Fungal Infections
National Institutes of Health
Grant: 5K22HL125593-03
Expression, regulation, and role of enhancer RNAs in T helper cells
National Institutes of Health
Grant: 3R35GM138283-03S1
Dissecting host-pathogen interactions through the lens of genomics
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial
Additional file 1 of GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
Additional file 1 of GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events